Anika Therapeutics (ANIK) Change in Cash (2010 - 2026)

Anika Therapeutics (ANIK) has reported Change in Cash for 17 consecutive years, with -$2.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Cash fell 1178.43% year-over-year to -$2.6 million in Q2 2026; TTM through Jun 2026 was -$14.8 million, a 52.82% decrease from a year earlier, with the FY2025 full-year figure at $322000.0, up 102.05% from the prior year.
• Change in Cash was -$2.6 million for Q2 2026 at Anika Therapeutics, up from -$16.5 million in the prior quarter.
• Over five years, Change in Cash peaked at $5.6 million in Q3 2023 and troughed at -$16.5 million in Q1 2026.
• A 5-year average of -$3.1 million and a median of -$3.1 million in 2022 frame the typical range for Change in Cash.
• Across the five-year window, Change in Cash sank 1474.51% in 2023 and jumped 1162.33% in 2025, its largest moves.
• Over 5 years, Change in Cash stood at -$1.4 million in 2022, then surged by 252.83% to $2.2 million in 2023, then slumped by 335.06% to -$5.2 million in 2024, then soared by 90.23% to -$509000.0 in 2025, then slumped by 412.38% to -$2.6 million in 2026.
• The last three Change in Cash figures came in at -$2.6 million (Q2 2026), -$16.5 million (Q1 2026), and -$509000.0 (Q4 2025), per Business Quant data.